XRAY DENTSPLY SIRONA Inc.

Dentsply Sirona Appoints Glenn Coleman as Chief Financial Officer

Dentsply Sirona Appoints Glenn Coleman as Chief Financial Officer

CHARLOTTE, N.C., Sept. 22, 2022 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced that Glenn Coleman has been appointed Executive Vice President and Chief Financial Officer, effective September 26, 2022. He succeeds Barbara Bodem, who has served as Interim Chief Financial Officer since May 2022. Ms. Bodem will remain with the company and continue to serve as an advisor to Mr. Coleman until October 24, 2022.

Mr. Coleman brings 30 years of financial management expertise to Dentsply Sirona. He joins the Company from Integra Lifesciences Holdings Corporation (“Integra”), where he most recently served as Executive Vice President and Chief Operating Officer and previously held the role of Chief Financial Officer. Prior to Integra, Mr. Coleman held numerous financial management positions at leading global businesses, including Curtiss-Wright Corporation and Alcatel-Lucent.

Simon Campion, Chief Executive Officer of Dentsply Sirona, said, “We are pleased to have Glenn join us in the CFO role. He is a transformational leader with a strong history of driving value creation and sustainable growth. Over the course of his career, he has overseen financial and operational functions across several geographies and industries, including healthcare. Glenn, like me, is a high-integrity leader who shares our commitment to accountability, operational rigor, discipline, and execution. I have no doubts that he will be a great thought partner for me and the other members of the leadership team. Glenn’s leadership will be instrumental as we move forward with the previously announced review of the Company’s business and operations including competitive positioning and portfolio, margin enhancement opportunities, and capital structure.”

Mr. Coleman said, “I’m excited to join Dentsply Sirona as the Company prepares to enter its next chapter. I look forward to working with Simon and rest of the team to bring greater focus and discipline to our execution, advance our financial, operational, and strategic goals, and ultimately deliver long-term growth and value creation.”

Mr. Campion continued, “On behalf of the Company, I would like to express our gratitude to Barbara for her service as Interim CFO. During her tenure, Barbara enhanced key financial processes, helped build improved management systems, and advanced our top operational priorities. We look forward to continuing to benefit from her exceptional skill and leadership during the transition.”

About Glenn Coleman

Mr. Coleman previously served as Executive Vice President & Chief Operating Officer at Integra Lifesciences Holdings Corporation; a role held since 2019. As Chief Operating Officer, Mr. Coleman led operations and most of Integra’s talent force, including clinical, R&D, manufacturing, and quality functions while also leading the international team. Mr. Coleman was previously Integra’s Chief Financial Officer overseeing the finance department, including accounting and financial reporting, budgeting, internal audit, tax, treasury, investor relations, and information technology while also leading the international business. Prior to Integra, Mr. Coleman spent 25 years in financial management positions with leading global businesses, including Curtiss-Wright Corporation and Alcatel-Lucent, and began his career at PricewaterhouseCoopers LLP.

Mr. Coleman earned a Bachelor of Science from Montclair State University and has been a CPA in New Jersey for more than 25 years.

About Dentsply Sirona

Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarters is located in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit  for more information about Dentsply Sirona and its products.

Contact Information

Investors:

Andrea Daley

VP, Investor Relations



Press: 

Marion Par-Weixlberger 

VP, Corporate Communications and PR

88 

 



EN
22/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DENTSPLY SIRONA Inc.

 PRESS RELEASE

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleare...

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system’s significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology’s applicability in endodontics, periodontics, TMJ, tooth extraction, and ort...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Dentsply Sirona Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 2 March 2026 in which we reassessed the appropriateness of the ratings in the context ...

Dentsply Sirona Inc: 2 directors

Two Directors at Dentsply Sirona Inc bought/maiden bought 55,000 shares at between 13.469USD and 14.148USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch